Figure Legends
Figure 1. General proliferative response. A) Bars represent percentage of positive cases in CD3+cells in both conventional LTT (C-LTT) and drug-primed-moDCs LTT (dDC-LTT) in NIDHR patients and healthy controls; B) Dots and bars represent proliferation index in dDC-LTT in different cell subpopulations in NIDHR patients and healthy controls; C) Bars represent percentage of positive cases using dDC-LTT combining different cell subpopulations in NIDHR patients and healthy controls. Comparisons in terms of positivity by X2 test and proliferation index by Kruskal-Wallis test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Figure 2. Proliferative response of CD3+cells in different clinical entities. A) Box plot represents proliferation index of CD3+ cells on different clinical entities studied in both C-LTT (in white) and dDC-LTT (in grey); B) Bars represent percentage of positive cases on different clinical entities studied in both C-LTT (in white) and dDC-LTT (in grey). Differences in the proliferation index have been performed using Mann–Whitney U test. Comparisons in terms of positivity have been performed using X2 test (*p < 0.05; ***p < 0.001).
Figure 3. Proliferative response of the different cell subpopulations based on the clinical entity. Dots and bars represent proliferation index in dDC-LTT in different cell subpopulations in NIDHR patients with A) SJS-TEN; B) MPE; C) AGEP. Bars represent percentage of positive cases using dDC-LTT combining different cell subpopulations in NIDHR patients (in grey) in D)SJS-TEN; E) MPE; F) AGEP and healthy controls (in white). Proliferation index comparisons between cell populations have been performed using Kruskal-Wallis test. Comparisons in terms of positivity have been performed using X2 test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Figure 4. Cell subpopulations positivity based on the clinical entity. A) Bars represent percentage of positive cases of CD4+Th1 (in white) and CD4+Th2 cells (in grey) in SJS, MPE, and AGEP patients; B) Bars represent percentage positive cases of NKIFN-γ (in white) and NKPerf cells (in grey) in SJS, MPE, and AGEP patients.
Figure S1. Flow cytometry strategy. A) Selection of proliferative CFSEdimCD3+ cells in unstimulated cells, cells stimulated with PHA, and cells stimulated with the culprit drug: B) Selection of cell subpopulations strategy.
Figure S2. ROC curves. ROC curve analysis of CD3+ cells in C-LTT and dDC-LTT in A) NIDHRs patients and healthy controls; B) SJS-TEN patients; C)MPE patients; D) AGEP patients. Arrows represent the Proliferation index value with the best balance between sensitivity and specificity.